for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agile Therapeutics Inc

AGRX.OQ

Latest Trade

2.38USD

Change

0.22(+10.19%)

Volume

1,919,234

Today's Range

2.16

 - 

2.48

52 Week Range

0.35

 - 

2.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Agile Therapeutics Reports Third-Quarter 2019 Financial Results

Oct 28 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.08.Q3 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.SAYS CASH EXPECTED TO ENABLE COMPANY TO FUND OPERATIONS THROUGH END OF Q1 2020.SAYS RESUBMITTED TWIRLA NDA IN Q2 OF 2019 AND HAS BEEN ASSIGNED A NOVEMBER 16, 2019 PDUFA GOAL DATE.

Agile Therapeutics Announces Pricing Of $12 Million Underwritten Public Offering Of Common Stock

Aug 2 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS ANNOUNCES PRICING OF $12 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 12.6 MILLION COMMON SHARES PRICED AT $0.95PER SHARE.

Agile Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock

Aug 1 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.

Agile Therapeutics Reports Q2 Loss Per Share $0.08

Aug 1 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.08.Q2 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.AGILE THERAPEUTICS- AS OF JUNE 30, CO HAD $10.6 MILLION OF CASH AND CASH EQUIVALENTS COMPARED TO $7.8 MILLION OF CASH AND CASH EQUIVALENTS AS OF DEC. 31, 2018.

Agile Therapeutics Appoints CFO

July 18 (Reuters) - Agile Therapeutics Inc <AGRX.O>::SAYS DENNIS P. REILLY APPOINTED CFO.AGILE THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER.APPOINTMENT OF DENNIS P. REILLY AS CHIEF FINANCIAL OFFICER EFFECTIVE AUGUST 5, 2019.

Agile Therapeutics Says On July 8, 2019, CFO Informed He Has Accepted A Position With A Private Co

July 11 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS INC - ON JULY 8, 2019, SCOTT M. COIANTE, CFO, INFORMED HE HAS ACCEPTED A POSITION WITH A PRIVATE COMPANY.AGILE THERAPEUTICS INC - COIANTE WILL BE DEPARTING COMPANY AFTER FILING OF COMPANY'S QUARTERLY REPORT ON FORM 10-Q FOR PERIOD ENDING JUNE 30, 2019.AGILE THERAPEUTICS INC - COMPANY HAS INITIATED A SEARCH FOR HIS SUCCESSOR.AGILE THERAPEUTICS INC - JOSEPH D'URSO, CONTROLLER, WILL SERVE AS INTERIM PRINCIPAL FINANCIAL OFFICER AFTER COIANTE LEAVES COMPANY.

Agile Therapeutics Announces FDA Acceptance Of The NDA Resubmission Of Twirla

May 22 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF THE NDA RESUBMISSION OF TWIRLA.AGILE THERAPEUTICS INC - FDA ASSIGNS PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF NOVEMBER 16, 2019.

Agile Therapeutics Resubmits New Drug Application (NDA) For Its Transdermal Low-Dose Contraceptive Patch, Twirla

May 17 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS RESUBMITS NEW DRUG APPLICATION (NDA) FOR ITS TRANSDERMAL LOW-DOSE CONTRACEPTIVE PATCH, TWIRLA®.AGILE THERAPEUTICS INC - AGILE RESUBMITTED NDA IN RESPONSE TO A DECEMBER 2017 COMPLETE RESPONSE LETTER (CRL) FROM FDA.AGILE THERAPEUTICS - RESUBMITTED NDA INCLUDES RESULTS FROM COMPARATIVE WEAR STUDY CONDUCTED AT REQUEST OF FDA TO ADDRESS QUESTIONS ON IN VIVO ADHESION.AGILE THERAPEUTICS INC - EXPECT FDA TO ACKNOWLEDGE SUBMISSION AS A COMPLETE RESPONSE IN APPROXIMATELY THIRTY DAYS.AGILE THERAPEUTICS - EXPECT FDA TO PROVIDE WITH A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE THAT WE ANTICIPATE WILL BE BASED ON A 6-MONTH REVIEW.AGILE THERAPEUTICS - RESUBMITTED NDA ALSO INCLUDES RESULTS FROM STUDY TO ADDRESS FDA'S QUESTIONS ON ADDITIONAL INFORMATION ON MANUFACTURING PROCESS.

Agile Therapeutics Reports Q1 Loss Per Share $0.13

May 2 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.13.Q1 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA.CASH EXPECTED TO ENABLE COMPANY TO FUND OPERATIONS INTO Q4 OF 2019.COMPANY PLANS TO RESUBMIT TWIRLA NDA IN Q2 OF 2019.AS OF MARCH 31, 2019, AGILE HAD $11.6 MILLION OF CASH AND CASH EQUIVALENTS.

Agile Therapeutics Q4 Loss Per Share $0.11

March 12 (Reuters) - Agile Therapeutics Inc <AGRX.O>::AGILE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.11.Q4 EARNINGS PER SHARE ESTIMATE $-0.15 -- REFINITIV IBES DATA.CASH EXPECTED TO ENABLE COMPANY TO FUND OPERATIONS INTO Q4 OF 2019.COMPANY PLANS TO RESUBMIT TWIRLA NDA IN Q2 OF 2019.AS OF DECEMBER 31, 2018, AGILE HAD $7.8 MILLION OF CASH AND CASH EQUIVALENTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up